Clinico-pharmacological aspects of choice and safety of NSAIDs in patients with cerebrovascular disease against a background of rheumatoid arthritis

Abstract

The retrospective study evaluated the risk of using non-steroidal antiinflammatory drugs (NSAIDs) for the treatment of back pain in patients with cerebrovascular disease against a background of rheumatoid arthritis. Acute cardio-and cerebrovascular events were reported in 9.7% of subjects treated with NSAIDs. Adverse effects during treatment were associated with diclofenac and nimesulide. Overall risks were low in the group treated with etoricoxib, allowing for all patients to undergo scheduled courses of NSAID therapy, including upon follow-up visits